Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Edward Carr on LinkedIn: Revumenib Shows Promise for Advanced

ASH: Novel menin inhibitors show promise for patients with

MEN1 mutations mediate clinical resistance to menin inhibition

Clinical Trial Results National Cancer Institute

Transforming NCI Cancer Clinical Trials - NCI

Treatment National Cancer Institute

MEN1 mutations mediate clinical resistance to menin inhibition

May 15 2012 - The ASCO Post

Namrata Gautam on LinkedIn: Signals released from dying cancer

Revumenib Shows Promise in Acute Leukemia - CancerConnect